Premium
Greenwich LifeSciences Inc (GLSI)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to p... Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -4.11 | -17.1894604768 | 23.91 | 24.55 | 16.52 | 184420 | 20.01627657 | CS |
| 4 | -9.54 | -32.5153374233 | 29.34 | 29.93 | 16.52 | 162053 | 23.16353674 | CS |
| 12 | -3.24 | -14.0625 | 23.04 | 30.26 | 16.52 | 140178 | 24.34463666 | CS |
| 26 | 2.65 | 15.4518950437 | 17.15 | 34.1 | 16.35 | 306175 | 25.01316669 | CS |
| 52 | 10.83 | 120.735785953 | 8.97 | 34.1 | 7.78 | 210446 | 21.01184167 | CS |
| 156 | 9.97 | 101.424211597 | 9.83 | 34.1 | 7.58 | 93540 | 18.79149814 | CS |
| 260 | -24.2 | -55 | 44 | 48.96 | 6.8241 | 89349 | 17.86840706 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
